Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript

Cellectis remains a high-risk, clinical-stage biotechnology firm whose financial stability is tethered to volatile, non-recurring milestone payments rather than a sustainable commercial revenue model.
Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 12, 2026 | -$0.61-238.9% vs -$0.18 | $4M-75.9% vs $16M |
Q3 2026 Aug 6, 2026 | -$0.22+16.3% vs -$0.26 | $7M-37.5% vs $11M |
Q2 2026 May 11, 2026 | -$0.18+30.3% vs -$0.26 | $8M-31.6% vs $11M |
Q2 2026 Mar 19, 2026 | -$0.26-27.9% vs -$0.20 | $12M-8.9% vs $13M |
Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript

Cellectis NASDAQ: CLLS said its cash runway is expected to extend into the second half of 2028 once its planned restructuring is fully implemented, giving the gene editing company time to reach anticipated initial clinical readouts for its two lead programs.
HEAL-101 a atteint jusqu'à 70 % d'édition in vivo d'APOC3, avec une activité limitée au foie, et a confirmé une réduction de 76 % des triglycérides dans des modèles murins (ESGCT 2026); lancement de l'essai de phase 1 IIT en Chine dans les temps, avec des données cliniques préliminaires attendues au second semestre 2027.
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today reported financial results for the third quarter 2026 ended September 30, 2026, and provided a business update.
Benchmark CLLS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cellectis S.A. (CLLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.03 | $103.43M | -1.59 | 75.76% | -115.48% | -94.24% | — | |
| $40.19 | $3.88B | -8.52 | -89.97% | -1812.07% | -25.59% | — | |
| $21.01 | $2.16B | -20.54 | 120.01% | -73.04% | -9.69% | — | |
| $1.77 | $271.63M | -3.76 | 25.39% | -144.95% | -130.43% | — | |
| $9.77 | $1.1B | -3.21 | 16.92% | -805.75% | -64.73% | — | |
| $1.05 | $122.39M | -1.04 | -51.24% | -2619.64% | -73.92% | — |
Cellectis S.A. (CLLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CLLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cellectis S.A. (CLLS) stock FAQ — growth, dividends, profitability & financials explained
Cellectis S.A. (CLLS) reported $56.6M in revenue over the trailing twelve months. Revenue was $72.9M in fiscal year 2025. That is 1679% more than the $4.1M of fiscal year 2007.
Cellectis S.A. (CLLS) grew revenue by 0.5% over the trailing twelve months, compared with the twelve months before.
No. Cellectis S.A. (CLLS) reported a net loss of $65.3M over the trailing twelve months.
Cellectis S.A. (CLLS) had a return on equity (ROE) of -94.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Cellectis S.A. (CLLS) had negative free cash flow of $44.1M over the trailing twelve months.